Miguel Regueiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Miguel Regueiro has a total of 243 co-authors. Here are the top co-authors by number of shared publications:
Kevin E. Kip
Research Center, College of Nursing, University of South Florida, Tampa, Florida
7 shared publicationsLeonard Baidoo
Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine Center, Pittsburgh, Pennsylvania
6 shared publicationsScott Plevy
Janssen Research & Development, LLC, Spring House, Pennsylvania
4 shared publicationsWolfgang Schraut
Division of Gastrointestinal Surgery, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
4 shared publicationsArthur M. Barrie
University of Pittsburgh Medical Center
3 shared publicationsDavid Binion
University of Pittsburgh School of Medicine
3 shared publications
Latest Publications
- Open Access
- 18 January 2018
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 24 (2) , 296-297
It’s Too Soon to Count Out Vedo for Postoperative Crohn’s Disease
Most Crohn’s disease patients who undergo an intestinal resection will have postoperative recurrence. Factors associated with the highest risk for postoperative recurrence include smoking, penetrating or perforating disease, and prior Crohn’s disease surgery. The available data suggest that probiotics, corticosteroids, and 5-aminosalicylates are of little benefit in preventing postoperative recurrence. Antibiotics, specifically metronidazole and ornidazole, have been shown to be of some benefit in preventing postoperative recurrence, but most cannot tolerate these long-term, and the benefit is lost when these medications are discontinued. Azathioprine and 6-Mercaptopurine are efficacious in maintaining remission in patients with moderate to severe Crohn’s disease, but when used in the postoperative setting, approximately one-half of patients have recurrence and many patients are intolerant. To date, the most effective medication to prevent recurrence, especially in high-risk patients, is to initiate an anti–tumor necrosis factor (anti-TNF) within 4 weeks of surgery.1,2 The recent American Gastroenterology Association technical review and guidelines also support the use of anti-TNFs postoperatively, but the benefit must be weighed against risk and the patient’s personal preferences taken into account.3,4
- 18 January 2018
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 24 (2) , 296-297
Open AccessIt’s Too Soon to Count Out Vedo for Postoperative Crohn’s Disease
Most Crohn’s disease patients who undergo an intestinal resection will have postoperative recurrence. Factors associated with the highest risk for postoperative recurrence include smoking, penetrating or perforating disease, and prior Crohn’s disease surgery. The available data suggest that probiotics, corticosteroids, and 5-aminosalicylates are of little benefit in preventing postoperative recurrence. Antibiotics, specifically metronidazole and ornidazole, have been shown to be of some benefit in preventing postoperative recurrence, but most cannot tolerate these long-term, and the benefit is lost when these medications are discontinued. Azathioprine and 6-Mercaptopurine are efficacious in maintaining remission in patients with moderate to severe Crohn’s disease, but when used in the postoperative setting, approximately one-half of patients have recurrence and many patients are intolerant. To date, the most effective medication to prevent recurrence, especially in high-risk patients, is to initiate an anti–tumor necrosis factor (anti-TNF) within 4 weeks of surgery.1,2 The recent American Gastroenterology Association technical review and guidelines also support the use of anti-TNFs postoperatively, but the benefit must be weighed against risk and the patient’s personal preferences taken into account.3,4
- 4 August 2017
- Published by Springer Nature
- p. 59-79
Use of Biologics in the Postoperative Management of Crohn’s Disease
- 4 August 2017
- Published by Springer Nature
- p. 59-79
Use of Biologics in the Postoperative Management of Crohn’s Disease
- 1 August 2017
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 15 (8) , 1148-1153.e4
Constructing an Inflammatory Bowel Disease Patient–Centered Medical Home
- 1 August 2017
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 15 (8) , 1148-1153.e4
Constructing an Inflammatory Bowel Disease Patient–Centered Medical Home
- 7 June 2017
- Published by Springer Nature
- p. 533-541
Postoperative Surveillance and Management of Crohn’s Disease
- 7 June 2017
- Published by Springer Nature
- p. 533-541
Postoperative Surveillance and Management of Crohn’s Disease
- Open Access
- 1 December 2016
- Published by Wolters Kluwer Health in The American Journal of Gastroenterology Supplements
- Vol. 3 (3) , 4-7
Refining Treatment Paradigms in Inflammatory Bowel Disease: Assessing the Options for Individualized Therapy
- 1 December 2016
- Published by Wolters Kluwer Health in The American Journal of Gastroenterology Supplements
- Vol. 3 (3) , 4-7
Open AccessRefining Treatment Paradigms in Inflammatory Bowel Disease: Assessing the Options for Individualized Therapy
- Open Access
- 1 June 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (7) , 1568-1578
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection
- 1 June 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (7) , 1568-1578
Open AccessInfliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection
- 16 April 2016
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 18 (5) , 1-6
A Practical Approach to Preventing Postoperative Recurrence in Crohn’s Disease
Postoperative Crohn’s disease recurrence remains common, and preventing additional surgery remains a challenge. A critical step to postoperative management of Crohn’s disease is being able to identify patients who should receive immediate postoperative therapy from the patients who can wait for recurrence prior to starting medications. All patients, regardless of their risk for recurrence, are advised to undergo a colonoscopy at 6 to 12 months after surgery to evaluate for endoscopic evidence of Crohn’s disease. Further management of patients depends on symptoms and the presence or absence of endoscopic recurrence.
- 16 April 2016
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 18 (5) , 1-6
A Practical Approach to Preventing Postoperative Recurrence in Crohn’s Disease
Postoperative Crohn’s disease recurrence remains common, and preventing additional surgery remains a challenge. A critical step to postoperative management of Crohn’s disease is being able to identify patients who should receive immediate postoperative therapy from the patients who can wait for recurrence prior to starting medications. All patients, regardless of their risk for recurrence, are advised to undergo a colonoscopy at 6 to 12 months after surgery to evaluate for endoscopic evidence of Crohn’s disease. Further management of patients depends on symptoms and the presence or absence of endoscopic recurrence.
- 29 October 2015
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (3) , 865-871
Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) has been linked to an increased risk of coronary heart disease and stroke. Dyslipidemia is a well-established risk factor for cardiovascular disease. The aim of this study was to investigate the long-term lipid profiles in a large cohort of IBD patients. Data of patients from an IBD registry who had more than one measurement of total cholesterol and triglyceride levels during the follow-up period were analyzed. The lipid profiles of IBD patients were compared to those of the general population according to National Health and Nutrition Examination Survey (2009–2012). Quartiles of cholesterol or triglyceride levels in relation to surrogate markers of disease severity were analyzed. Seven hundred and one IBD patients [54 % Crohn’s disease (CD), 46 % ulcerative colitis (UC)] were included. IBD patients had less frequent high total cholesterol and high LDL cholesterol (6 vs. 13 and 5 vs. 10 %) and more frequent low HDL and high triglycerides (24 vs. 17 and 33 vs. 25 %) compared to the general population (all p < 0.001). Median total cholesterol levels were lower and median triglycerides higher in CD compared to UC (171 vs. 184; 123 vs. 100 mg/dL; both p < 0.001). In the multiple regression analysis, lipid profile was independently associated with hospitalizations (low cholesterol) and IBD surgeries (low cholesterol and high triglycerides). Low total cholesterol and high triglyceride levels are more frequent in IBD patients (in particular CD) compared to healthy controls and are independently associated with more severe disease.
- 29 October 2015
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (3) , 865-871
Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) has been linked to an increased risk of coronary heart disease and stroke. Dyslipidemia is a well-established risk factor for cardiovascular disease. The aim of this study was to investigate the long-term lipid profiles in a large cohort of IBD patients. Data of patients from an IBD registry who had more than one measurement of total cholesterol and triglyceride levels during the follow-up period were analyzed. The lipid profiles of IBD patients were compared to those of the general population according to National Health and Nutrition Examination Survey (2009–2012). Quartiles of cholesterol or triglyceride levels in relation to surrogate markers of disease severity were analyzed. Seven hundred and one IBD patients [54 % Crohn’s disease (CD), 46 % ulcerative colitis (UC)] were included. IBD patients had less frequent high total cholesterol and high LDL cholesterol (6 vs. 13 and 5 vs. 10 %) and more frequent low HDL and high triglycerides (24 vs. 17 and 33 vs. 25 %) compared to the general population (all p < 0.001). Median total cholesterol levels were lower and median triglycerides higher in CD compared to UC (171 vs. 184; 123 vs. 100 mg/dL; both p < 0.001). In the multiple regression analysis, lipid profile was independently associated with hospitalizations (low cholesterol) and IBD surgeries (low cholesterol and high triglycerides). Low total cholesterol and high triglyceride levels are more frequent in IBD patients (in particular CD) compared to healthy controls and are independently associated with more severe disease.
- 17 October 2015
- Published by Springer Nature
- p. 101-116
Teleconferences to Facilitate Multidisciplinary Care and Education in IBD
- 17 October 2015
- Published by Springer Nature
- p. 101-116
Teleconferences to Facilitate Multidisciplinary Care and Education in IBD
- 19 October 2014
- Published by Springer Nature
- p. 255-266
Treatment of Distal/Left-Sided Ulcerative Colitis
- 19 October 2014
- Published by Springer Nature
- p. 255-266
Treatment of Distal/Left-Sided Ulcerative Colitis